Presentation is loading. Please wait.

Presentation is loading. Please wait.

Wei Ai, M.D., Ph.D. June 2012. I. Lymphoma: bendamustine II. CLL/SLL: Btk inhibitor III. Pre-B ALL: Bite biphasic antibody IV. Multiple Myeloma: Carfilzomib.

Similar presentations


Presentation on theme: "Wei Ai, M.D., Ph.D. June 2012. I. Lymphoma: bendamustine II. CLL/SLL: Btk inhibitor III. Pre-B ALL: Bite biphasic antibody IV. Multiple Myeloma: Carfilzomib."— Presentation transcript:

1 Wei Ai, M.D., Ph.D. June 2012

2 I. Lymphoma: bendamustine II. CLL/SLL: Btk inhibitor III. Pre-B ALL: Bite biphasic antibody IV. Multiple Myeloma: Carfilzomib

3

4

5 National LymphoCare Study N = 2728 Friedberg, et al., JCO 2009 R + chemotherapy: RegimenUsers (%) RCHOP 55.0% RCVP23.1% R-fludarabine15.5% Other6.4%

6

7  Newly diagnosed indolent lymphoma or mantle cell lymphoma: - Follicular lymphoma (grade 1-3a), small lymphocytic lymphoma, marginal zone lymphoma, wadenstroms, mantle cell lymphoma (elderly)  Stage III and IV  Meet criteria for initiating treatment

8

9

10

11

12

13

14

15

16

17

18

19

20 Samantha Mary Jaglowski, et al. The Ohio State University

21

22  BTK inhibitor, an oral agent, showed promising activity as a single agent in untreated elderly pts (>65 yo) with CLL/SLL (John Byrd 2012 ASCO) - N = 26 - ORR 81%, CR 12% with medium f/u 14 mos  Ofatumumab is active in fludarabine- or alemtumumab-refractory CLL/SLL pts: ORR approximately 50% Wierda, et al., JCO 2010

23  Ibrutinib 420 mg po qd  Oftumumab mg C2, day mg C2,days 8, 15, mg C3, days 1, 8, 15, mg C4-8, day 1 only

24  To determine the toxicity of the combination regimen - Tolerability is defined as no more than 1 DLT in the first 6 pts treated for 2 cycles  To evaluate ORR at one year: N = 27, including the initial 6

25  CLL/SLL or Richter’s transformation  Two or more prior therapy, including a purine analog- containing regimen  More than 10% CD20 expression on CLL cells by flow cytometry  Adequate organ functions

26

27

28

29

30

31

32

33  Ibrutinib combined with ofatumumab is a well tolerated and highly active regimen in patients with relapsed and refractory CLL/SLL

34

35 Max Topp et al.

36

37 Topp, et al., JCO % 15 ug/m 2 /24 hrs CIV x 4 weeks, 2 weeks off, q 6wk-cycle

38  Dose-finding Phase: - Cohorts: 1, 2a, 2b  Expansion Phase:  Dosing: CIV 4 wks on, 2 wks off, for up to 5 cycles - CR/CRh within the first 2 cycles -> allo  Primary Endpoint: CR/CRh within 2 cycles

39  R/R ALL, > 5% blasts in BM  Ph+ and relapsed after allo were permitted

40  Selected dose for expansion cohort based on lowest treatment-related AEs (3/5 pts): 5ug/m2/d CIV week 1, then 15ug/m2/d CIV thereafter

41 N = 23 Median Age 31 (21 – 66) Refractory1 (4%) Relapsed21 (91%) 1 st relapse <= 18 mos 9 (43%) 1 st relapse > 18 mos4 (19%) >= 2 nd relapse8 (38%) Prior SCT10 (43%) Ph +2 (9%) T (4,11)1 (4%) Blasts in BM >60%12 (52%) 10% - 60%6 (24%) < 10%4 (17%)

42  Cytokine release syndrome - Risks: high tumor burden ans without cytoreductive phase - Prevention: cytoreduction 5ug/m2 wk 1 and give Dex for BM>50%  CNS Adverse Events: - 3 seizures and 3 encephalopathy: fully reversible - all 6 pts continued at 5 ug/m2  One pt died of fungal infection

43  CR/CRh: 17/23 pts (74%)  All but 2 responders achieved molecular remission  High remission rate in all pt groups, including Ph+  13 pts received an allogeneic SCT  With a median follow-up of 4.5 months, median duration of response was 8.9 for all cohorts, not yet reached for the expansion cohort

44  Well-tolerated at 5 ug/m2/d followed by 15 ug/m2/d CIV, 4 weeks on, 2 weeks off  High hematologic and molecular response rate  Median duration of complete hematologic response was 8.9 months  Median survival was 9 months

45 Carfilzomib Coming to the Front-line

46  Disease status - High risk, intermediate risk vs low risk - special clinical scenarios: plasma leukemia, renal failure  Patient factors - Transplant eligibility - PS and comorbidity  Clinical benefit - response and OS - QOL  Toxicity and convenience  Cost

47

48

49

50

51  Newly approved second-in-class proteasome inhibitor  Well tolerated, no neurotoxicity  Overcome bortezomib resistance in vitro  Active alone and in combination regimens for relapsed/refractory MM Kuhn et al., Blood 2007, O’Connor Clin Cancer Res 2009, Wang, M et al., JCO 2011 Abstract 8052, Vij, et al., Blood, 2012

52 CMP carfilzomib, melphalan, prednisone CYCLONE carfilzomib, cyclophosphamide thalidomide dexamethasone CRd carfilzomib, lenalidomide dexamethasone Key CriteriaTransplant ineligible >65 yo Transplant eligibleTransplant ineligible or eligible Comparative or Parent regimens VMPCyBorD CTD RVD,VTD, VTD

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70  Carfilzomib: 20mg/m 2 first week, 27mg/m 2 thereafter

71

72

73

74 Stringent complete response (sCR) in patients with newly diagnosed multiple myeloma (NDMM) treated with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) AJ Jakubowiak, 1 K Griffith, 2 D Dytfeld, 3 DH Vesole, 4 S Jagannath, 5 T Anderson, 2 B Nordgren, 2 K Detweiler-Short, 2 D Lebovic, 2 K Stockerl-Goldstein, 6 T Jobkar, 2 S Wear, 7 A Al-Zoubi, 2 A Ahmed, 2 M Mietzel, 2 D Couriel, 2 M Kaminski, 2 M Hussein, 8 H Yeganegi, 9 R Vij 6 1 University of Chicago, Chicago, IL; 2 University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; 3 Poznan University of edical Sciences, Poznan, Poland; 4 John Theurer Cancer Center, Hackensack, NJ; 5 Mount Sinai Medical Center, New York, NY; 6 Washington University School of Medicine, St. Louis, MO; 7 Multiple Myeloma Research Consortium, Norwalk, CT; 8 Celgene, Inc, Summit, NJ; 9 Onyx Pharmaceuticals, South San Francisco, CA

75 Objectives Primary Phase 1: MTD of CRd Phase 1/2: rate of ≥nCR Secondary Overall response rate (≥PR) TTP, DOR, PFS, and OS Tolerability and toxicity For transplant candidates, evaluate the impact of CRd on stem cell mobilization Evaluate prognostic factors and markers of response 4

76 Eligibility Key inclusion criteria Newly-diagnosed MM requiring first-line therapy 1 - Transplant-eligible and -ineligible Measurable disease per IMWG Criteria 1 ECOG performance status 0-2 Key exclusion criteria Grade 3/4 peripheral neuropathy ANC <1.0 x10 9 /L, Hgb <8.0 g/dL, platelets <75,000/µL Creatinine clearance <50 mL/min or serum creatinine ≥2 g/dL Serious co-morbidities 1. Durie BGM, et al. Leukemia. 2006;20:

77 Treatment Schema Transplant- eligible and -ineligible patients CRd Induction - CRd Cycles 1-4CRd Cycles 5-8 Transplant-eligible ≥PRASCT Stem cell collection CRdLenalidomide Maintenance(off protocol) CRd Cycles 9-24LEN Cycles 25+ Until disease progression or unacceptable toxicity Assessments on D1 and 15 of C1 and D1 thereafter using modified IMWG Criteria with nCR Cycles CFZ mg/m 2 Days 1-2, 8-9, LEN 25 mg Days 1-21 DEX 40 mg weekly Cycles 1- 4, 20 mg weekly Cycles 5-8 Cycles CFZ on Days and only CFZ, LEN, DEX at last best tolerated doses Cycles 25+ LEN at last best tolerated dose 1. Jakubowiak AJ, et al. Blood. 2011;118: abstract

78 Best Response Median 12 cycles (range 1-25 ) ≥PR ≥VGPR≥nCRsCR All patients N=53 There was no difference by disease stage and cytogenetics 9

79 Progression-free Survival Median follow-up of 13 months (range 4-25) 2 patients progressed All patients with sCR have maintained response for median 9 months (range 1-20) 12

80 Updated Toxicity of CRd Induction Thrombocytopenia Grade 3/4 Anemia Neutropenia Any grade Hyperglycemia Edema Hypophosphatemia Fatigue Muscle cramping LFTs Rash Diarrhea Infection Phlebitis Peripheral neuropathy Dyspnea DVT/PE Renal Constipation Mood alterations Patients (%) Toxicity for cycles 1-8 is similar to previously reported 1 Limited dose modifications 1. Jakubowiak AJ, et al. Blood. 2011;118: abstract

81 CMP carfilzomib, melphalan, prednisone N = 35 CYCLONE carfilzomib, cyclophosphamide thalidomide dexamethasone N = 24 CRd carfilzomib, lenalidomide dexamethasone N = 53 Transplant ineligible >65 yo Transplant eligibleTransplant ineligible or eligible Comparative or Parent regimens VMPCyBorD CTD RVD,VTD, VTD ORR - CR - sCR - nCR - VGPR - PR 31(89%) 1 (3%) 14 (40%) 16 (46%) 23 (96%) 7 (29%) 11 (46%) 5 (21%) 52 (98%) 33 (62%) 22 (42%) 11 (20%) 10 (19%) 9 (17%)

82  Highly active as a first-line treatment for MM  The quality of response seems improved in some studies  Tolerability seems improved with minimum peripheral neuropathy, although comparison with SQ bortezomib remain to be investigated

83  Lymphoma and CLL/SLL The Stil trial established R-Benda as the preferred first-line treatment for FL and MCL Ofatumumab + ibrutinib (Btk inhibitor) is highly active in relapsed/refractory CLL/SLL  Acute Leukemia Blinatumumab (Bite biphasic antibody) is highly active in relapsed/refractory ALL  Multiple Myeloma Carfilzomib is moving to the front line

84

85 Grade 3/4 CHOP-R N =253 BR N = 261 Neutropenia69%29% lymphopenia43%74%

86

87 Topp, et al., JCO 2011


Download ppt "Wei Ai, M.D., Ph.D. June 2012. I. Lymphoma: bendamustine II. CLL/SLL: Btk inhibitor III. Pre-B ALL: Bite biphasic antibody IV. Multiple Myeloma: Carfilzomib."

Similar presentations


Ads by Google